HIV infection and hepatitis B seroprevalence among antenatal clinic attendees in Niger, West Africa

fection and hepatitis B seroprevalence among antenatal clinic attendees in Niger, West Africa Short Report (2718) Total Article Views Authors: Mamadou S, Ide M, Maazou ARA, Aoula B, Labo S, Bozari M Published Date December 2011 Volume 2012:4 Pages 1 - 4 DOI: http://dx.doi.org/10.2147/HIV.S27881 Sa dou Mamadou1,2, Moussa Ide3, Amadou Roufa Ali Maazou2, Balki Aoula2, Seyni Labo4, Mamane Bozari4 1Laboratory of Bacteriology-Virology, Faculty of Health Sciences, University Abdou Moumouni, Niamey, Niger; 2National Reference Laboratory for STI/HIV/TB, Niamey, Niger; 3Coordination Board, Inter-Sectorial Program on STI/HIV/AIDS, Niamey, Niger; 4National Center for Social Sciences Expertise, Niamey, Niger Abstract: This transversal study was suggested in order to estimate the nationwide seroprevalences of HIV infection and hepatitis B among 495 pregnant women in Niger in 2008. The study detected anti-HIV antibodies with Genscreen Plus HIV Ag/Ab Ultra Kit (Bio-Rad; Hercules, CA), Vironostika HIV Uni-Form II Ag/Ab (bioMérieux; Marcy-l’Etoile, France), and ImmunoComb II HIV 1 and 2 BiSpot (Orgenics; Yavne, Israel). HBsAg was detected by Monolisa HBsAg Ultra (Bio-Rad) and ImmunoComb II HBsAg (Orgenics). The rates obtained were 2.02% (95% confidence intervals (CI): 1.03%–3.81%) and 16.16% (95% CI: 13.09%–19.77%), respectively. There were no significant variations according to environment, region, age, marital status, educational level, antecedent of surgery and transfusion. But these data need a large sample, and periodic updates for a better planning of activities in the framework of a national reproductive health program, including prevention of mother-to-child HIV transmission.